Japan Approves Multiple Firsts, Leqembi, Arexvy, Leqvio, and More

September 26, 2023
Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab). Arexvy became the...read more